Chemistry42驱动，英矽智能提名ISM3830为临床前候选化合物，靶向CBLB用于晚期肿瘤免疫治疗 (VIDEO) InSilico Medicine This video is under embargo. Please login to access this video. Caption 英矽智能提名ISM3830为临床前候选药物（PCC），用于晚期肿瘤免疫治疗。该候选药物具有AI赋能的创新分子骨架，是一款潜在同类最佳的口服、高选择性CBLB抑制剂。 Credit 英矽智能 Usage Restrictions None License Original content Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.
